1-(2-吗啉-4-基-1H-咪唑-5-基)乙酮 | 88723-37-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(2-吗啉-4-基-1H-咪唑-5-基)乙酮
• 英文名称: 1-[2-(4-morpholinyl)-1H-imidazol-4-yl]ethanone
• 英文别名: Ethanone, 1-[2-(4-morpholinyl)-1H-imidazol-4-yl]-；1-(2-morpholin-4-yl-1H-imidazol-5-yl)ethanone
• CAS: 88723-37-9
• 化学式: C₉H₁₃N₃O₂
• 分子量: 195.221
• InChiKey: ORZMSESZRCKLRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-吗啉-4-基-1H-咪唑-5-基)乙酮 在 乙酸铵 、 sodium hydride 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 2-amino-4-(3-bromophenyl)-6-[1-methyl-2-(morpholin-4-yl)-1H-imidazol-4-yl]nicotinonitrile
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023
• 作为产物：
  描述：

  N,N-dimethyl-2-morpholino-1H-imidazole-1-sulfonamide 在 盐酸 、 正丁基锂 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.67h， 生成 1-(2-吗啉-4-基-1H-咪唑-5-基)乙酮
  参考文献：
  名称：

  [EN] LRRK2 INHIBITORS
  [FR] INHIBITEURS DE LRRK2

  摘要：

  公开号：

  WO2012178015A3

文献信息

• [EN] 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDO[2,3-D]PYRIMIDINE A DISUBSTITUTION 5,7
  申请人：ABBOTT LAB

  公开号：WO2000023444A1

  公开（公告）日：2000-04-27

  A method of inhibiting adenosine kinase by administering one of more compounds of formula (I), wherein R?1, R2, R3 and R4¿ are defined, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.

  一种通过给予式(I)中的一个或多个化合物来抑制腺苷激酶的方法，其中R1、R2、R3和R4被定义，以及包含上述化合物的治疗有效量与药学可接受载体组合的制药组合物，以及一种治疗哺乳动物的脑缺血、癫痫、疼痛感知、炎症和败血症的方法，包括给予哺乳动物上述化合物的治疗有效量，制备上述化合物的方法以及具有上述式中R1、R2、R3和R4分别被定义的化合物。
• LRRK2 INHIBITORS
  申请人：Bounaud Pierre-Yves

  公开号：US20140205537A1

  公开（公告）日：2014-07-24

  Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.

  本文提供了抑制或部分抑制富含亮氨酸重复激酶活性的化合物。本文还提供了治疗中枢神经系统疾病的方法，包括给予富含亮氨酸重复激酶抑制剂的治疗。
• [EN] LRRK2 INHIBITORS<br/>[FR] INHIBITEURS DE LRRK2
  申请人：ZENOBIA THERAPEUTICS INC

  公开号：WO2012178015A3

  公开（公告）日：2013-05-10
• 5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors
  作者：Mark A. Matulenko、Chih-Hung Lee、Meiqun Jiang、Robin R. Frey、Marlon D. Cowart、Erol K. Bayburt、Stanley DiDomenico、Gregory A. Gfesser、Arthur Gomtsyan、Guo Zhu Zheng、Jeffery A. McKie、Andrew O. Stewart、Haixia Yu、Kathy L. Kohlhaas、Karen M. Alexander、Steve McGaraughty、Carol T. Wismer、Joseph Mikusa、Kennan C. Marsh、Ronald D. Snyder、Marilyn S. Diehl、Elizabeth A. Kowaluk、Michael F. Jarvis、Shripad S. Bhagwat

  DOI：10.1016/j.bmc.2005.03.023

  日期：2005.6

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.